Multiple system atrophy and Parkinson’s disease are progressive nervous system disorders that affect everyday movements. Multiple system atrophy is rarer and tends to progress more quickly.

Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that ... olivopontocerebellar atrophy and Shy-Drager syndrome. MSA is considered a rare disease affecting ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease ...

Intravenous immunoglobulin (IVIG) has anti-inflammatory properties with multiple mechanisms of action. IVIG inhibits autoreactive T cells, suppresses autoantibodies through anti-idiotypic ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders –– Topline Data Expected in Early ...

which has more parkinsonian symptoms but is relatively unresponsive to the usual therapy for Parkinson’s disease (i.e., levodopa). Some of the atypical parkinsonian disorders, such as progressive ...

AC Immune SA has divulged compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of multiple system atrophy (MSA), Parkinson’s dementia, Lewy body ...

A new study contradicts previous research that suggests transurethral resection of the prostate (TURP) in patients with Parkinson disease ... patients with multiple system atrophy incorrectly ...

Given that alpha-synuclein pathology is also observed in a range of related diseases, such as multiple systems atrophy and some forms of Alzheimer's disease, the results from this study are far ...